Home・Elenco Azioni・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

4.28 3.63

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.13

Massimo

4.29

Metriche Chiave
By Trading Economics
Entrata	11M 51M
Vendite	6.5M 113M
P/E Media del settore	5.45 57.371
EPS	0.31
Margine di Profitto	45.374
Dipendenti	100
EBITDA	6.2M 81M

Dividendi
By Acuity
Utili prossimi	9 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-7.1M 720M
Apertura precedente	0.65
Chiusura precedente	4.28

Notizie sul Sentiment di mercato

By Acuity

91%

12 / 340 Classifica in Healthcare

Ironwood Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 ago 2026, 20:06 UTC

Ironwood Pharmaceuticals Inc shares are lower during Thursday's session, reversing earlier gains amid rising crude oil prices and increasing U.S. Treasury yields.

19 ago 2026, 19:46 UTC

Ironwood Pharmaceuticals shares are higher, supported by declining bond yields and broader market trends. The stock is trading near the upper end of its one-month range.

18 ago 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today amid cautious market sentiment influenced by rising treasury yields and inflation concerns.

17 ago 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, maintaining its position near the upper end of its one-month range amid rising Treasury yields and inflation concerns.

14 ago 2026, 23:01 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, following a drop in U.S. retail sales that raised concerns about consumer spending and economic health.

13 ago 2026, 23:36 UTC

Ironwood Pharmaceuticals Inc shares are lower during after-market hours, with no specific news identified to explain the decline. Trading activity remains routine.

12 ago 2026, 19:21 UTC

Ironwood Pharmaceuticals is higher Wednesday, buoyed by overall strength in U.S. stocks, despite a recent pullback earlier in the session.

11 ago 2026, 22:06 UTC

Ironwood Pharmaceuticals Inc shares are higher in after-market trading, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

10 ago 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today, with no specific news identified. The stock remains significantly down since Friday's close amid broader market volatility.

7 ago 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc shares are higher during Friday's session, maintaining a position above the 20-day moving average, despite earlier fluctuations.

6 ago 2026, 23:06 UTC

Ironwood Pharmaceuticals shares are higher in after-market hours, reflecting positive movement since Thursday's close. No specific news was identified to explain the price action.

5 ago 2026, 23:02 UTC

Ironwood Pharmaceuticals shares are higher in after-market trading, continuing a notable increase since Wednesday's close, despite no specific news identified.

4 ago 2026, 23:01 UTC

Ironwood Pharmaceuticals Inc. shares are lower in after-market trading, showing routine volatility while remaining above the 20-day moving average. No specific news was identified.

3 ago 2026, 19:26 UTC

Ironwood Pharmaceuticals is trading higher today, continuing a rally since Friday's close, amid broader market gains and falling energy prices.

31 lug 2026, 23:26 UTC

Ironwood Pharmaceuticals Inc shares are trading higher in after-market hours, maintaining upward momentum since Friday's close. No specific news was identified for this movement.

30 lug 2026, 20:51 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, despite broader market gains. The stock remains below its 20-day moving average and near a one-month low.

29 lug 2026, 20:04 UTC

Ironwood Pharmaceuticals Inc shares are trading lower amid broader market dynamics, including rising oil prices due to escalating Middle East tensions.

27 lug 2026, 20:06 UTC

Ironwood Pharmaceuticals shares are higher today, reflecting broader market dynamics, despite earlier declines and a significant drop in oil prices.

24 lug 2026, 23:26 UTC

Ironwood Pharmaceuticals shares gained modestly in after-market trading, following a volatile session amid broader turmoil in the bond market.

20 lug 2026, 18:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, reaching a session peak before settling within its one-month range. No specific news was identified for today's movement.

Confronto tra pari

Modifica del prezzo

Ironwood Pharmaceuticals Inc Previsione

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Ironwood Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

12 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.